Hepatitis C

Increasing survival in HCV-related hepatocellular carcinoma

The benefits of direct-acting antiviral (DAA) therapy for hepatitis C in patients with hepatocellular carcinoma (HCC) have been debated. In a retrospective cohort study of 797 patients with HCV-related HCC with a complete response to HCC treatment (383 patients received DAAs, 414 patients did not), DAA therapy was associated with a significant reduction in the risk of death (HR 0.54; 95% CI 0.33 0.90). Furthermore, this association differed by whether or not patients had achieved a sustained virologic response (SVR) to DAA therapy, with risk of death reduced in those who had achieved SVR (HR 0.29; 95% CI 0.18 0.47), but not in those who did not achieve SVR (HR 1.13; 95% CI 0.55 2.33).

DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

Source Link

odiseases.com

diseases, diagnosis and treatment methods, drugs and their side effects on this site. online diseases, diagnosis and treatment methods

Related Articles

Back to top button
%d bloggers like this: